What does research tell us about how DMTs affect the body’s immune response to COVID-19 vaccines?
Watch the International Progressive MS Alliance webcast
Professor Thompson wins the 2021 lifetime achievement award for outstanding research into the understanding and treatment of MS
This article delves into the land of genetics, explaining the method called ‘Mendelian randomisation’, which scientists use to learn about links between genes and disease.
Biomarkers is a term that often comes up when we talk about MS treatment and clinical trials - but what are they and why are they important?
Deadline for MSIF grants and fellowships is 30 June 2021
MSIF is proud to announce the recipients of the 2020 McDonald Fellowships and Du Pré Grants, from Iran, Zambia, Brazil, Turkey, and Argentina
Helen Onuorah receives the 2020 Young Investigator Award on her project "Racial inequalities in MS research participation"
New research funded by the International Progressive MS Alliance looks at ways that nerve fibres protect themselves from damage.
Stichting MS celebrates 40 years of MS research with a campaign on resilience. The Dutch MS organisation has partnered with local researchers and the UK MS Society to put their work in the spotlight.
The Global Patient Reported Outcomes for MS Initiative is looking for an International Program Manager with great organizational, communication, and negotiation skills.
Each year, seasoned riders from around the world take on over 400km of the toughest climbs from the Tour De France just weeks before the official race. It's the ride that every cyclist dreams of, but only the toughest can complete.
A new international study has mapped a type of immune cell, the microglia, in the human and mouse brain for the first time. Microglia are thought to play a role in the progression of MS. This research has changed the understanding of how these cells function, and has important implications for MS.
New study shows that early use of high efficacy treatment for MS improves long term disability outcomes, rather than starting on a moderately effective therapy and escalating to a stronger medication.
In a recent study, scientists have shown that people with MS who have food allergies are more likely to experience clinical attacks and lesions in the brain than those without allergies or with other allergies that are unrelated to food.
MSIF’s Atlas of MS with new data on the number of people living with MS across the world, and the challenges they face.
Driving global change - progress made by the global MSIF movement
976 chemicals were screened to assess their impact on MS.
A trial has compared a cancer chemotherapy to MS treatments, but further research is needed to understand how effective the treatment is in comparison to other MS treatments.
Studies show that improved MS medications and advances in MRI technology have led to an increased rate of doctors changing courses of MS treatment and a reduced tolerance of any sign of disease activity, with doctors more readily switching treatments in cases of low disease activity.
MSIF is pleased to announce the winner of this year’s Young Investigators Award: Dr Silke Häusser-Kinzel.
MSIF is proud to announce the recipients of the 2018 McDonald fellowships and Du Pre grants
The ‘Immune balance’ partnership unites health charities, the government, scientists and corporate bodies in a joint effort to improve understanding of the immune system in chronic immune diseases like MS.
The Scientific Committee of the French MS Research Support Foundation (ARSEP) has selected recipients for its annual research grants and fellowships.
MS Ireland took World MS Day as an opportunity to launch a pioneering research report, designed to help Ireland become a world leader in MS research.
World MS Day will take place on 30 May. The 2018 campaign is called Bringing Us Closer and the theme is Research.
New research shows that sun exposure over a lifetime can change the course of MS.
The deadline for applications for McDonald fellowships and Du Pré Grants is 30 June 2018
Tools for the #bringinguscloser campaign for World MS Day 2018 are now available to download.
The Association for the Fight Against MS (ALCEM) presents the Miguel Pablo Gallardo award and the Proyecto Investigación (Research Project) award.
The European Commission has approved the first disease-modifying therapy, ocrelizumab, for early primary progressive MS (PPMS).
MSIF is proud to announce the recipients of the 2017 McDonald fellowships and Du Pre grants
Chemistry of brain inflammation linked to mood changes in MS
Prof. Sørensen, one of the world’s prominent clinical neurologists in multiple sclerosis, recognised for lifetime achievement in improving understanding and treatment of MS.
A meeting of minds took place at the recent International Progressive MS Alliance event in London
Diagnosis of MS is getting faster and more efficient but new research suggests there are still ways to improve diagnosis
A new study recently published uses ‘real-world’ data to investigate the effects of disease modifying therapies on secondary progressive MS
Resistance exercise increases the thickness of the brain cortex in some people with MS
A review shows complementary therapies are yet to be proven for MS
MSIF and the Dutch MS Research Foundation launch Global MS Research Booster Award for researchers studying the cause of MS
Matthew Miles, Chief Executive of MS Research Australia, shared insights on how technology is revolutionising research, treatment, diagnosis, and more
An exciting opportunity to lead the search for improved understanding and treatments for MS and better access to treatments and healthcare
North African ethnicity is found to be a significant predictor of fast progression
International study looks at long-term progression in people with MS following stem cell therapy
Researchers uncover a molecule that promotes regeneration of myelin
Survey results show a high hypothetical interest in physician-assisted death in people with MS
French MS organisation ARSEP celebrates 26th annual conference
MS Ireland launches two major new publications on early treatment and diagnosis of MS
Ocrelizumab has been approved as a treatment for both relapsing and primary progressive MS in the US
Study suggests neurofilament levels may be used as a marker of damage to brain cells in MS
Use of oral hormonal contraceptive drugs does not appear to be associated with greater risk of relapses
The latest and most thorough studies do not show an association between CCSVI and MS
Researchers find fampridine safe and effective in the long term for improving walking speed
Low vitamin D levels and smoking consistently associated with MS progression
The deadline for applications for McDonald fellowships and Du Pré Grants is 30 June 2017
Advanced MRI shows sodium concentration in gray matter better explains cognition than atrophy in MS
People diagnosed with CIS who received early treatment are less likely to convert to MS
Optical coherence tomography may be used to test the effect of drugs in relapsing-remitting MS trials
Some family members of people with MS show possible early signs of the disease without symptoms
A biomarker in cerebrospinal fluid is associated with a higher risk of MS in people with CIS
Further evidence shows the role of vitamin D in MS risk, especially during pregnancy
250 people with progressive MS are taking part in the SPRINT-MS trial for ibudilast
Professor Alan Thompson highlights some of 2016’s research discoveries in MS
A new study fails to replicate the role of a gene in developing primary progressive MS
A retrospective study of rituximab use in MS shows evidence for its safety and effectiveness
People with MS display increased deficiencies in social cognition
People from countries with higher latitudes are found to have an earlier onset of MS
Study shows alemtuzumab can improve pre-existing disability in relapsing-remitting MS
Researchers assess whether changes in the retina can be used as a marker of MS activity
Study shows that alemtuzumab is more effective than interferon in reducing disease activity in relapsing remitting MS
Researchers note a relationship between HRT and quality of life in women with MS after menopause
Study identifies that migraine and fibromyalgia are frequently misdiagnosed as MS
A phase II trial shows safety and efficacy of amiselimod
We are pleased to announce the recipients of our 2016 McDonald Fellowships and Du Pré grants
Researchers and health professionals gather for the latest updates and research findings on treatment, care and management of MS
MRI is not a predictor of long term MS outcomes
Research shows no difference in disease activity in successive pregnancies
Early treatment of clinically isolated syndrome shows beneficial effects for relapse rate and cognitive functioning
Researchers investigate a link between brain lesions and severity of sexual issues in women with MS
Siponimod study shows reduced MS activity and low relapse rates with no new safety concerns
Research in the USA finds no link between salt intake and time to relapse in children with MS
Researchers find a link between MS and microbes living in the gut
Researchers find that birth month affects the risk of MS in the UK
HLA alleles are found to be associated with brain atrophy and a younger age of MS onset in women
A mutation in a gene called NR1H3 could increase the risk of progressive MS
German study asks whether recipients of mitoxantrone are more likely than the general population to develop cancers
Rebooting immune system provides long term relief for aggressive relapsing MS in Canadian study
Researchers find that suddenly stopping fingolimod may lead to severe worsening of symptoms in MS
Drugs used for metabolic syndrome may reduce MS activity in people with MS and obesity
Research suggests that higher brain growth is linked to lower risk for disability progression in people with MS
Australian researchers aim to predict future worsening of disability in people with relapse-onset MS
Microbes in the body’s gastrointestinal system appear to change how myelin genes are expressed in the brain
Retinal thickness can be used as a measure to predict worsening disability in MS
Review shows previous measures of memory rehabilitation were not reflective of daily life
Researchers find men with MS experience more chronic health problems at the time of diagnosis
Swedish study favours rituximab over fingolimod for those at risk of progressive multifocal leukoencephalopathy
The role of genes in NMO appears to vary depending on a person’s ethnicity
Research suggests that high consumption of coffee may protect brain cells from damage
French researchers compare oral and injectable drugs for relapsing-remitting MS
An international study looks at the safety and efficacy of a drug similar to fingolimod
A drug currently used to treat epilepsy could be used to protect cells in the optic nerve for people with all types of MS
How common is obesity in people with MS and is it related to disability?
A recent study has failed to show any benefit for Rituximab in people with secondary progressive MS
A new trial has failed to show Fingolimod has any effect of in primary-progressive MS
Study recommends including cognitive evaluation when measuring NEDA
Genes, lifestyle, and environment in adolescence could be important factors in the development of MS
Step training is shown to be effective in improving stepping, standing balance, and coordination
Hormones released during pregnancy could be a potential treatment for relapsing remitting MS
Autologous Haematopoietic Stem Cell Transplantation (AHSCT) is being investigated as a treatment for MS
People with RIS evolve to PPMS at the same frequency as expected from general MS populations
New data supports the use of oral steroid methylprednisolone to treat MS relapses
New research shows no association between increasing blood vitamin D levels and reduced inflammation in relapsing-remitting MS
Sexual dysfunction is a common but often overlooked and undertreated symptom in MS
MS researcher Arman Eshaghi answers questions from around the world
Long-term follow-up studies could help determine predictive factors for long-term clinical outcomes
Study suggests that longer observation time is necessary for more reliable results
Switching from natalizumab to an alternative drug may prevent disease reactivation
Arman Eshaghi will answer your questions
Results show daclizumab to be effective in reducing relapse rate and new lesions in relapsing-remitting MS
A selection of fellowships and grants that MSIF members and partners offer to MS researchers around the world
Which of these MS research areas would you like to hear more about?
Which of these MS research areas would you like to hear more about?
We spoke to an Argentinian researcher studying the correlation between melatonin and MS
Chemical in the brain involved in signaling may play a role in progressive MS
The results of a seven-year follow-up study confirm the safety and efficacy of fingolimod
A German study shows that exclusive breastfeeding does not increase the risk of relapse after childbirth
Current and past fellows of MSIF and ECTRIMS come together in Barcelona to share experiences
Study suggests that melatonin could be a possible cause of seasonal changes in MS disease activity
On 6 October, 650 people affected by MS gathered in Barcelona for the ‘Living with MS Day’ event
Our highlights from the world’s largest scientific conference on multiple sclerosis
The results from a phase III clinical trial of Ocrelizumab in primary progressive MS are announced at ECTRIMS
A recent study suggests OCT could be used as an indicator of neuronal damage in MS
Research shows that certain brain structures involved in effort-reward functions play a role in fatigue in MS
A study to assess whether nabiximols could be used to improve walking in people with MS
Recovery from early relapses can potentially delay or prevent onset of progressive MS
A trust has launched in New Zealand to fund research to improve the lives of people with MS
There is a need to identify direct biomarkers of inflammation within the central nervous system
Researchers are looking for new biomarkers of disease, which could also recognise progression of MS in a reasonable time
A method for early detection of Natalizumab-associated progressive multifocal leukoencephalopathy in the absence of clinical symptoms
Identifying risk factors for developing further attacks and disability accumulation in patients with “clinically isolated syndrome"
Researchers in Canada have investigated the natural history of 500 people with primary progressive MS
The results of a multi-centre, phase II, randomized trial
Radial shock wave therapy has been used to treat spasticity and pain in Italy
Study suggests that early spinal neurodegeneration may underlie clinical impairment
Evidence shows that smoking increases the risk of developing MS and accelerates disease progression
Research and clinical trials are taking place around the world, trying to find and improve treatments for MS
Thousands of scientists are undertaking research into all aspects of MS, furthering our understanding of the disease and how to prevent, treat and manage it.